Cipla Ltd Forensic Report - SOIC x StockScans Report

as of Jul 2026

Cipla’s record is one of steady operating cash generation and a clean audit trail, but it carries three large, unresolved overhangs: a two-decade drug-pricing dispute with demands now exceeding ₹2,000 crore, a pattern of impairment charges that has erased over ₹1,000 crore of value in five years, and a cluster of regulatory and tax enforcement actions that remain open.

Key findings

  1. A ₹2,011 crore overcharging dispute runs without any provision Major - NPPA demand notices for alleged overcharging under DPCO 1995, dating from 1998, aggregate to ₹2,011 crore (principal ₹863 crore, interest ₹1,148 crore) as of FY2025-26. The Supreme Court stayed 50% recovery in 2003 subject to payment of the balance, and Cipla has deposited ₹175.08 crore under protest; on 15 July 2025 it voluntarily deposited a further ₹27.07 crore without prejudice to its stance that nothing is due. The company has made no provision for the ₹2,011 crore in demands, stating it expects a favourable outcome.
  2. Impairments have eroded over ₹1,000 crore in five years, with a fresh ₹122.53 crore hit in FY26 Major - An impairment charge of ₹122.53 crore was recorded on intangible assets in FY26, following ₹93.57 crore in FY25, ₹144.11 crore in FY23, ₹40.76 crore in FY22, and ₹46.32 crore in FY21, a cumulative ₹447.29 crore over five years. A fair-value loss of ₹190.07 crore was recognised in OCI on the Ethris GmbH investment in FY26 after reassessing recoverability. Earlier exceptional charges include ₹183.19 crore on the Pulmazole intangible in FY24, ₹182.41 crore of goodwill impairment in FY23, and ₹182.12 crore on the Avenue Therapeutics investment in FY22.
  3. U.S. FDA remediation, a ₹9.77 crore GST penalty, and ₹559 crore in income tax demands remain open Major - The Indore facility carries an OAI classification from the U.S. FDA, delaying the Advair product and forcing a tech transfer to a U.S. site. The Goa facility received VAI status in FY2024-25 and was subsequently inspected with two observations, with classification awaited as of the Q4 FY26 call. On 15 January 2025, the GST Authority imposed a penalty of ₹9.77 crore for inadmissible input tax credit and delayed vendor payments; Cipla calls the penalty arbitrary and will appeal. Outstanding income tax demands for AYs 2015-16 to 2022-23 stand at ₹559.18 crore including interest.
  4. A labour-law change drives a ₹275.91 crore exceptional charge, while a subsidiary amalgamation and segment restatement reshape the books Minor - Cipla recorded an exceptional charge of ₹275.91 crore in FY26 for increased gratuity and leave liability triggered by the new Labour Codes effective 21 November 2025. The Board approved amalgamation of wholly owned subsidiary Inzpera Healthsciences Limited, which had a negative net worth of ₹36.10 crore, with an appointed date of 1 April 2026, subject to NCLT approval. From FY26 the company reports a single segment, restating the prior-year comparative that previously showed two segments.
  5. Promoter holding slips to 29.21% with zero pledge, while a ₹25 crore MD incentive and an independent-director reappointment drew institutional dissent Minor - Promoter and promoter group shareholding fell from 34.23% as of 15 February 2022 to 29.21% as of FY2025-26, with zero shares pledged throughout. A one-time long-term incentive of ₹25 crore payable to the outgoing MD&GCEO was approved on 16 May 2024 with 76.37% in favour, but public institutional holders voted 41.89% against. The reappointment of an independent director beyond age 75 was approved on 26 March 2026 with 83.01% in favour, while public institutional holders voted 28.30% against.
  6. Operating cash flow still covers profit, but the ratio has weakened as capital allocation tilts toward CWIP and dividends Minor - Cumulative CFO of ₹23,398 crore exceeded cumulative PAT of ₹21,111 crore over FY21-FY26, but the annual CFO/PAT ratio declined from 1.56x in FY21 to 1.02x in FY26. CWIP stood at ₹2,042 crore as of FY26, representing 37% of gross PP&E. Free cash flow was ₹2,364 crore in FY26, down from ₹3,868 crore in FY25, while the FY26 dividend recommendation of ₹13 per share implies a payout of approximately ₹1,049 crore.
  7. Revenue recognition is a persistent Key Audit Matter, but customer concentration is absent and contract assets are modest Clean - The auditor has identified revenue recognition as a Key Audit Matter in every annual report from FY2020 through FY2026, citing significant judgments for discounts, returns, rebates, and price adjustments, particularly in the US business. No single external customer represented 10% or more of group revenue in any of those years. The consolidated contract asset for expected returns was ₹21.62 crore as at 31 March 2026.

What to watch

Bottom line: This is a disclosed and audited record with cumulative cash flow that covers cumulative profit. The risk is concentrated in three places: a ₹2,011 crore pricing dispute that has run for over two decades without a provision, a habit of writing down acquired intangibles and investments that has consumed more than ₹1,000 crore in five years, and a set of open regulatory and tax enforcement actions spanning the U.S. FDA and Indian tax authorities. Watch the Supreme Court hearing, the next annual impairment test, and the Goa facility classification.